In a randomized phase II clinical trial, we have shown previously that the adoptive transfer of ex vivo Hsp70-peptide TKD and IL-2-activated autologous (patient-derived) NK cells provides a survival benefit in patients with advanced non-small-cell lung carcinoma [34]. This evidence concerns the gene IL2 and non-small cell lung carcinoma.